Hamblett KJ et al. |
Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability. |
2016 |
Mol. Pharm. |
pmid:27248573
|
Ponte JF et al. |
Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates. |
2016 |
Bioconjug. Chem. |
pmid:27174129
|
Fan Y et al. |
Effects of modulation of pentose-phosphate pathway on biosynthesis of ansamitocins in Actinosynnema pretiosum. |
2016 |
J. Biotechnol. |
pmid:27173582
|
Jacot W et al. |
Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. |
2016 |
Breast Cancer Res. Treat. |
pmid:27167986
|
Sandra K et al. |
Multiple heart-cutting and comprehensive two-dimensional liquid chromatography hyphenated to mass spectrometry for the characterization of the antibody-drug conjugate ado-trastuzumab emtansine. |
2016 |
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. |
pmid:27160547
|
Tsuda M et al. |
Abnormal Corneal Lesions Induced by Trastuzumab Emtansine: An Antibody-Drug Conjugate for Breast Cancer. |
2016 |
Cornea |
pmid:27149538
|
Kwon Y et al. |
Telangiectasia and Pulmonary Arterial Hypertension Following Treatment With Trastuzumab Emtansine: A Case Report. |
2016 |
Chest |
pmid:27055712
|
Martin M et al. |
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. |
2016 |
Ann. Oncol. |
pmid:27052654
|
Coiffier B et al. |
A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. |
2016 |
Br. J. Haematol. |
pmid:27010483
|
Sibaud V et al. |
T-DM1 extravasation: first description. |
2016 |
J Eur Acad Dermatol Venereol |
pmid:25879278
|
Krop IE et al. |
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer. |
2016 |
Breast Cancer Res. |
pmid:26979312
|
de Goeij BE and Lambert JM |
New developments for antibody-drug conjugate-based therapeutic approaches. |
2016 |
Curr. Opin. Immunol. |
pmid:26963132
|
Maass KF et al. |
Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design. |
2016 |
AAPS J |
pmid:26912181
|
Vankemmelbeke M and Durrant L |
Third-generation antibody drug conjugates for cancer therapy--a balancing act. |
2016 |
Ther Deliv |
pmid:26893243
|
Raja SM et al. |
Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition. |
2016 |
Oncotarget |
pmid:26859680
|
Kantarjian HM et al. |
A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. |
2016 |
Clin Lymphoma Myeloma Leuk |
pmid:26775883
|
Li JY et al. |
A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy. |
2016 |
Cancer Cell |
pmid:26766593
|
Catcott KC et al. |
Microscale screening of antibody libraries as maytansinoid antibody-drug conjugates. |
2016 |
MAbs |
pmid:26752675
|
Yan H et al. |
Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity. |
2016 |
Mol. Cancer Ther. |
pmid:26712117
|
|
Checkpoint Inhibitors Boost Power of Antibody-Drug Conjugate. |
2016 |
Cancer Discov |
pmid:26701087
|